Aprotinin and transfusion requirements in pediatric craniofacial surgery

Paediatric Anaesthesia

Volumn 24, Issue 2, 2014, Pages 141-145

  Ahmed, Zulfiqar ^a   Stricker, Lori ^b   Rozzelle, Arlene ^b   Zestos, Maria ^b  

^a OAKWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

aprotinin; blood transfusion; coagulation blood; pediatrics blood component transfusion

Indexed keywords

ANTIHISTAMINIC AGENT; APROTININ; CREATININE; DIPHENHYDRAMINE; PLACEBO; BLOOD SUBSTITUTE; COLLOID; CRYSTALLOID; HEMOSTATIC AGENT; ISOTONIC SOLUTION;

ANAPHYLAXIS; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BODY SURFACE; BODY WEIGHT; BRONCHOCONSTRICTION; CLINICAL ARTICLE; COLLOID; CRANIOFACIAL SURGERY; CREATININE BLOOD LEVEL; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FLUID RESUSCITATION; FOLLOW UP; HUMAN; HYPOTENSION; LENGTH OF STAY; LOADING DRUG DOSE; NEWBORN; OPERATION DURATION; PEROPERATIVE CARE; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TRANSFUSION; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; ADMINISTRATION AND DOSAGE; ADOLESCENT; CHILD; CONTROLLED STUDY; FACE; FEMALE; MALE; OPERATIVE BLOOD LOSS; PLASTIC SURGERY; POSTOPERATIVE HEMORRHAGE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; SURGERY; THERAPEUTIC USE;

ADOLESCENT; APROTININ; BLOOD LOSS, SURGICAL; BLOOD SUBSTITUTES; BLOOD TRANSFUSION; CHILD; COLLOIDS; ERYTHROCYTE TRANSFUSION; FACE; FEMALE; HEMOSTATICS; HUMANS; ISOTONIC SOLUTIONS; MALE; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; RECONSTRUCTIVE SURGICAL PROCEDURES;

EID: 84891836407     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/pan.12279     Document Type: Article

References (24)

1. Miller BE, Tosone SR, Tam VK, et al,. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg 1998; 66: 535-540.
2. Sniecinski RM, Karkouti K, Levy JH,. Managing clotting: a North American perspective. Curr Opin Anaesthesiol 2012; 25: 74-79.
3. D'Errico CC, Shayevitz JR, Martindale SJ, et al,. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg 1996; 83: 1193-1199.
4. Cole JW, Murray DJ, Snider RJ, et al,. Aprotinin reduces blood loss during spinal surgery in children. Spine 2003; 28: 2482-2485.
5. Urban MK, Beckman J, Gordon M, et al,. The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery. Spine 2001; 26: 1152-1156.
6. Jaquiss RD, Huddleston CB, Spray TL,. Use of aprotinin in pediatric lung transplantation. J Heart Lung Transplant 1995; 14: 302-307.
7. Dietrich W, Spannagl M, Jochum M, et al,. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990; 73: 1119-1126.
8. Royston D, Bidstrup BP, Taylor KM, et al,. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2: 1289-1291.
9. Rich JB,. The efficacy and safety of aprotinin use in cardiac surgery. Ann Thorac Surg 1998; 66: S6-S11.
10. Fergusson DA, Hébert PC, Mazer CD, et al,. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-2331.
11. Henry D, Carless P, Fergusson D, et al,. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 2009; 180: 183-193.
12. U. S. Food and Drug Administration. 2007 Safety alerts for human medical products. Aprotinin injection (marketed as Trasylol). Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm150815.htm. Accessed 25 January, 2013.
13. Murkin JM,. Lessons learned in antifibrinolytic therapy: The BART trial. Semin Cardiothorac Vasc Anesth 2009; 13: 127-131.
14. Stricker PA, Shaw TL, Desouza DG, et al,. Blood loss, replacement, and associated morbidity in infants and children undergoing craniofacial surgery. Pediatr Anesth 2010; 20: 150-159.
15. Williams GD, Ellenbogen RG, Gruss JS,. Abnormal coagulation during pediatric craniofacial surgery. Pediatr Neurosurg 2001; 35: 5-12.
16. D'Errico CC, Munro HM, Buchman SR, et al,. Efficacy of aprotinin in children undergoing craniofacial surgery. J Neurosurg 2003; 99: 287-290.
17. Kher A, Meldrum KK, Hile KL, et al,. Aprotinin improves kidney function and decreases tubular cell apoptosis and proapoptotic signaling after renal ischemia-reperfusion. J Thorac Cardiovasc Surg 2005; 130: 662-669.
18. Godfrey AM, Salaman JR,. Trasylol (aprotinin) and kidney preservation. Transplantation 1978; 25: 167-168.
19. Tsai AG, Cabrales P, Intaglietta M,. Microvascular perfusion upon exchange transfusion with stored red blood cells in normovolemic anemic conditions. Transfusion 2004; 44: 1626-1634.
20. Dietrich W,. Incidence of hypersensitivity reactions. Ann Thorac Surg 1998; 65: S60-S64.
21. Shaw AD, Stafford-Smith M, White WD, et al,. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358: 784-793.
22. Mangano DT, Tudor IC, Dietzel C, et al,. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-365.
23. Wilder NS, Kavarana MN, Voepel-Lewis T, et al,. Efficacy and safety of aprotinin in neonatal congenital heart operations. Ann Thorac Surg 2011; 92: 958-963.
24. Howell N, Senanayake E, Freemantle N, et al,. Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. J Thorac Cardiovasc Surg 2013; 145: 234-240.